Financing
Cash And Cash Equivalents And Restricted Cash Acquired In Connection With Eqrx Acquisition Net Of Transaction Costs
This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ1 2021
Last reportedQ4 2025Feb 25, 2026
How to read this metric
An increase indicates the successful acquisition of liquid assets from a target company, bolstering the balance sheet.
Detailed definition
This metric captures the cash and restricted cash balances acquired through business combinations or corporate acquisiti...
Peer comparison
Highly dependent on M&A activity; peers rarely report this unless they are actively acquiring.
Metric ID:
financing_cash_and_cash_equivalents_and_restricted_cash__efbef1Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $840.83M | $0.00 | $0.00 |
| YoY Change | — | — | — | -100.0% | — |
Range$0.00 – $840.83M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Cash And Cash Equivalents And Restricted Cash Acquired In Connection With Eqrx Acquisition Net Of Transaction Costs at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s cash and cash equivalents and restricted cash acquired in connection with eqrx acquisition net of transaction costs?
- Revolution Medicines, Inc. (RVMD) reported cash and cash equivalents and restricted cash acquired in connection with eqrx acquisition net of transaction costs of $0.00 in Q4 2025.
- What does cash and cash equivalents and restricted cash acquired in connection with eqrx acquisition net of transaction costs mean?
- Cash and restricted cash obtained specifically through the acquisition of another company.